Annick Desjardins MD FRCPC

Clinical Trials

• Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM) Start of enrollment: 2007 Apr 01

  Completed

  Phase 2

• Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma Start of enrollment: 2007 Jul 01

  Completed

  Phase 2

• Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas Start of enrollment: 2007 Jul 01

  Completed

  Phase 2

• Ph I Dasatinib + Erlotinib in Recurrent MG Start of enrollment: 2008 Jan 01

  Completed

  Phase 1

• PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas Start of enrollment: 2005 Oct 01

  Completed

  Phase 1

• Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma Start of enrollment: 2007 Nov 01

  Completed

  Phase 1

• Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG Start of enrollment: 2005 May 01

  Completed

  Phase 1

• Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas Start of enrollment: 2008 Feb 01

  Completed

  Phase 1

• Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) Start of enrollment: 2006 Feb 01

  Completed

  Phase 2

• Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma Start of enrollment: 2009 Jun 01

  Withdrawn

  Phase 1

• A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) Start of enrollment: 2008 Dec 01

  Terminated

  Phase 2

• Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG) Start of enrollment: 2009 Sep 01

  Completed

  Phase 2

• Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma Start of enrollment: 2009 Nov 01

  Completed

  Phase 1

• Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma Start of enrollment: 2009 Dec 30

  Completed

  Phase 2

• Study of Immunotoxin, MR1-1 Start of enrollment: 2006 Nov 01

  Terminated

  Phase 1

• Panitumumab and Irinotecan for Malignant Gliomas Start of enrollment: 2010 Feb 01

  Terminated

  Phase 2

• Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2011 Apr 01

  Terminated

  Phase 2

• A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Start of enrollment: 2011 Dec 01

  Completed

  Phase 2

• Pilot Study of Bone Marrow/Stem Cells in Grade IV Malignant Glioma Start of enrollment: 2012 Jun 01

  Completed

  Phase 1

• Bevacizumab Beyond Progression (BBP) Start of enrollment: 2013 Jan 01

  Completed

  Phase 2

• Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure Start of enrollment: 2013 Oct 01

  Terminated

  Phase 1

• Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma Start of enrollment: 2014 May 01

  Terminated

  Phase 1

• Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma Start of enrollment: 2016 Feb 01

  Completed

  Phase 2

• Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM Start of enrollment: 2018 May 30

  Terminated

  Phase 1

• Seizure Prophylaxis in Patients With Glioma or Brain Metastasis Start of enrollment: 2019 Jan 31

  Terminated

  Phase 2

• DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab Start of enrollment: 2020 Aug 26

  ACTIVE_NOT_RECRUITING

  PHASE2

• Monocyte Antigen Carrier Cells for Newly Diagnosed GBM Start of enrollment: 2023 Aug 01

  Withdrawn

  Phase 1

• Join now to see all